Bacillus Patents (Class 424/246.1)
-
Patent number: 8551498Abstract: The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed technique, useful in the pharmaceutical, veterinary and nutrition fields.Type: GrantFiled: September 16, 2011Date of Patent: October 8, 2013Assignee: Sanofi-Aventis S.p.A.Inventor: Tiziano Prato
-
Patent number: 8524223Abstract: A microorganism inhibits the growth of various plant pathogens, and is not reduced in its efficacy even when the microorganism is used in combination with a chemical pesticide. The microorganism is Bacillus subtilis KS1 strain (NITE BP-569). The plant disease control agent comprises a culture of the microorganism as an active ingredient.Type: GrantFiled: July 3, 2009Date of Patent: September 3, 2013Assignee: University of YamanashiInventors: Tsutomu Takayanagi, Shunji Suzuki, Seiichi Furuya
-
Publication number: 20130216577Abstract: The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus Bacillus, in treating digestive-related immune disorders by downregulating of cytokines and by inhibiting pathogenic or deleterious microorganisms in the gastrointestinal tract. Specific formulations of Bacillus coagulans for various immune disorders are elaborated.Type: ApplicationFiled: March 20, 2013Publication date: August 22, 2013Inventor: Ganeden Biotech, Inc.
-
EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES
Publication number: 20130189308Abstract: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.Type: ApplicationFiled: November 26, 2012Publication date: July 25, 2013Applicant: University of Central Florida Research Foundation, Inc.Inventor: Henry Daniell -
Patent number: 8492519Abstract: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.Type: GrantFiled: August 19, 2008Date of Patent: July 23, 2013Assignees: Hyglos Invest GmbH, bioMérieux S.A.Inventors: Holger Grallert, Michael Forchheim
-
Publication number: 20130183339Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicant: Intercell AGInventor: Intercell AG
-
Publication number: 20130183345Abstract: Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels.Type: ApplicationFiled: March 8, 2013Publication date: July 18, 2013Applicants: CATALYST ASSETS, LLCInventors: Lars Dyrskjøt Andersen, Torben Falck Orntoft, Joseph A. Sorge, Alexey Novoradovsky
-
Patent number: 8481043Abstract: Compositions and methods for intranasal delivery of antigens for immunization of a mammal are disclosed. Antigens include peptides, proteins, peptidomimetics, DNA, RNA, carbohydrates and phospholipids. The compositions contain at least one antigen and a permeation enhancer. The permeation enhancer can be a macrocyclic permeation enhancer, such as a Hsieh enhancer.Type: GrantFiled: June 4, 2010Date of Patent: July 9, 2013Assignee: CPEX Pharmaceuticals, Inc.Inventors: Nils Bergenhem, Lance Berman
-
Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
Patent number: 8481055Abstract: The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif.Type: GrantFiled: May 24, 2010Date of Patent: July 9, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dennis M. Klinman, Bruce Ivins, Daniela Verthelyi -
Publication number: 20130171192Abstract: A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox and anthrax.Type: ApplicationFiled: October 23, 2012Publication date: July 4, 2013Applicant: IRX Therapeutics, Inc.Inventor: IRX Therapeutics, Inc.
-
Publication number: 20130156728Abstract: The present invention provides a composition effective for a neurological disease or an autoimmune disease and methods of making and using the same.Type: ApplicationFiled: May 26, 2011Publication date: June 20, 2013Applicant: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. GovernmentInventor: Daniel L. Kaufman
-
Publication number: 20130149330Abstract: The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of Bacillus anthracis in an individual. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis or fragment thereof attached via a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies and/or cytotoxic T cells which inhibit or block Bacillus anthracis infection in an individual.Type: ApplicationFiled: February 5, 2013Publication date: June 13, 2013Applicant: MICROVAX, LLCInventor: MicroVAX, LLC
-
Publication number: 20130142825Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.Type: ApplicationFiled: May 26, 2011Publication date: June 6, 2013Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.Inventors: Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
-
Publication number: 20130115244Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: October 1, 2012Publication date: May 9, 2013Applicant: Yisheng Biopharma (Singapore) PTE. LTD.Inventor: Yisheng Biopharma (Singapore) PTE. LTD.
-
Patent number: 8425880Abstract: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.Type: GrantFiled: April 25, 2008Date of Patent: April 23, 2013Assignee: Nucryst Pharmaceuticals Corp.Inventors: Jeffrey B. Lyczak, Katherine Thompson, Katherine Turner, Paul Schechter
-
Patent number: 8414878Abstract: A bioengineering, in particular to develop novel probiotic preparations based on Bacillus-strain bacteria, which can be used for preventing and treating infectious diseases and disbiosis of a human being, farm animals and birds. The novel strains of B. subtilis 07 (VKPM No. B-8611) and B. licheniformis 09 (VKPM No. B-8610) exhibit a broad spectrum of antagonistic activity, high proteolytic and amylase activity and a distinct ability in terms of a lysozim production. Such strains do not compete with each other but enter into synergistic relations in the form of an increased antagonistic action of the biopreparation. The inventive biopreparation comprises the B. subtilis 07 VKPM No. B-8611 and B. licheniformis 09 VKPM No. B-8610 strains and a protective medium. Such biopreparation can also contain a solvent and/or filler and exhibits an increased antagonistic activity with respect to a wide range of pathogenic and opportunistic pathogenic microorganisms and a resistance to quite a number of antibiotics.Type: GrantFiled: April 28, 2005Date of Patent: April 9, 2013Inventors: Irina Grigorievna Osipova, Irina Borisovna Sorokulova, Elena Aleksandrovna Vasilieva, Sergei Gennadievich Trofimov, Vera Franzevna Evlashkina, Elena Yurievna Haritonova, Sergei Eduardovich Sarkisov, Natalia Vasilievna Tereshkina, Yurii Igorevich Ostroumov, Aleksandr Nikolaevich Doronin, Marina Aleksandrovna Kulichizkaya, Aleksandr Aleksandrovich Matveev
-
Patent number: 8409590Abstract: Anthrax antigens are provided that find use as immunogens and vaccines.Type: GrantFiled: February 11, 2005Date of Patent: April 2, 2013Assignee: Ligocyte Pharmaceuticals, Inc.Inventor: Susan Wimer-Mackin
-
Patent number: 8409591Abstract: The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus Bacillus, in treating digestive-related immune disorders by downregulating of cytokines and by inhibiting pathogenic or deleterious microorganisms in the gastrointestinal tract. Specific formulations of Bacillus coagulans for various immune disorders are elaborated.Type: GrantFiled: November 22, 2010Date of Patent: April 2, 2013Assignee: Ganeden Biotech, Inc.Inventors: Sean Farmer, Andrew R. Lefkowitz
-
Patent number: 8404247Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: June 23, 2011Date of Patent: March 26, 2013Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Patent number: 8398995Abstract: A method for inducing immune tolerance to type I diabetes in a mammal by mucosal delivery of an antigen involved in the induction of type I diabetes such as pro-insulin or insulin is disclosed. The antigen involved in the induction of type I diabetes is delivered together with an IL-10 secreting micro-organism such as Lactococcus lactis and a anti-CD3 antibody.Type: GrantFiled: October 9, 2009Date of Patent: March 19, 2013Assignee: Actogenix NVInventors: Pieter Rottiers, Veerle Snoeck
-
Patent number: 8394387Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: GrantFiled: July 31, 2007Date of Patent: March 12, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Patent number: 8388933Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.Type: GrantFiled: April 15, 2011Date of Patent: March 5, 2013Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
-
Patent number: 8389469Abstract: The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Bacillus anthracis and B. cereus bacteria and spores, and related conditions. The disclosure further relates to compositions comprising various phage associated lytic enzyme that rapidly and specifically detect and kill Bacillus anthracis and other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to Bacillus anthracis are also provided.Type: GrantFiled: May 31, 2006Date of Patent: March 5, 2013Assignee: The Rockefeller UniversityInventors: Pauline Yoong, Raymond Schuch, Daniel Nelson, Vincent A. Fischetti
-
Patent number: 8383084Abstract: Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method includes the steps of modifying a surface of a bacterial spore to increase adherence to a phagocyte; and ingesting the adherence-increased spore with the phagocyte, thereby destructing and killing the spore by blocking spore-induced phagocyte cell death, while increasing phagocyte activation level and production of antimicrobial and cytocidal agents such as NO and inflammatory cytokines. The adherence of spore to a phagocyte is increased after the surface thereof is coated with a glycoconjugate to form a glycoconjugate-coated spores. The glycoconjugate-coated spores also increase ingestion of the spores by phagocytes and facilitate phagosome-lysosome fusion, which in turn results in destruction and killing of bacterial spores via phagocytosis.Type: GrantFiled: February 22, 2007Date of Patent: February 26, 2013Inventor: Olga Tarasenko
-
Patent number: 8343495Abstract: Disclosed are compositions and methods for treating a subject infected with Bacillus anthracis or at risk for infection with B. anthracis. The compositions include and the methods utilize isolated or purified equine antisera against B. anthracis.Type: GrantFiled: January 11, 2010Date of Patent: January 1, 2013Assignee: Auburn UniversityInventor: Kenny V. Brock
-
Patent number: 8329187Abstract: Liquid-based phamaceutical and/or veterinary and/or nutraceutical compositions comprising non pathogenic sporogenic bacteria, component SP), and the following components: O) from 0.001 to 95% by weight of one or more oils selected from esters of C4-C32 acids, C4-C32, S) from 0 to 90% by weight of one or more amphiphilic compounds, selected from surfactants, polymers forming organized structures such as aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, AD) from 0 to 60% by weight of one or more additive compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, PA) from 0.001 to 70% of one or more compounds selected from food supplements and pharmaceutical and/or veterinary active principles, W) from 0.1 to 99.9% by weight of water or saline aqueous solution, optionally buffered, the sum of the percentages by weight of the components, excluding SP), is 100%.Type: GrantFiled: February 25, 2010Date of Patent: December 11, 2012Assignee: Neuroscienze Pharmaness S.C. A.R.L.Inventors: Paolo Lazzari, Paolo Fadda, Luca Pani
-
Patent number: 8313928Abstract: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA or a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.Type: GrantFiled: March 26, 2007Date of Patent: November 20, 2012Assignee: The Secretary of State for DefenseInventors: Ethel Diane Williamson, Julie Miller, Nicola Jane Walker, Leslie William James Baillie, Paula Thomson Holden, Helen Claire Flick-Smith, Helen Lisa Bullifent, Richard William Titball, Andrew William Topping
-
Patent number: 8277816Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus anthracis. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.Type: GrantFiled: February 13, 2007Date of Patent: October 2, 2012Assignee: Fraunhofer USA, Inc.Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuck, Marina Skarjinskaia
-
Publication number: 20120237544Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.Type: ApplicationFiled: September 21, 2010Publication date: September 20, 2012Applicant: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh
-
Patent number: 8252291Abstract: Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.Type: GrantFiled: June 1, 2011Date of Patent: August 28, 2012Assignees: The United States of America, as represented by the Secretary of Agriculture, State Research Center for Applied Microbiology & Biotechnology, Ministry of Health & Social Development, RF, as represented by the Director of the State Research Center for Microbiology & Biotechnology, Ministry of Health & Social Development, RFInventors: Norman J Stern, Edward A Svetoch, Boris V Eruslanov, Vladimir V Perelygin, Vladimir P Levchuk, Nikolay N Urakov, Larisa I Volodina, Yuri N. Kovalev, Tamara Y. Kudryavtseva, Victor D. Pokhilenko, Valery N. Borzenkov, Olga E. Svetoch, Eugeni V. Mitsevich, Irina P. Mitsevich
-
Patent number: 8246965Abstract: Bacillus isolates and compositions comprising the same are provided. Also provided are methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins.Type: GrantFiled: August 5, 2011Date of Patent: August 21, 2012Assignee: Montana State UniversityInventors: Barry Jacobsen, Nina K. Zidack, Rebecca Larson
-
Publication number: 20120201845Abstract: Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigens Immune responses that provide prophylactic and/or therapeutic treatments are preferred. Antigenic activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a dry or liquid formulation to the skin, patches and other medical devices may be used to deliver antigen for immunization.Type: ApplicationFiled: January 12, 2012Publication date: August 9, 2012Applicants: Command Judge AdvocateInventors: Gregory M. Glenn, Carl R. Alving
-
Patent number: 8227418Abstract: The present invention relates to the use of an alpha-defensin in the manufacture of a medicament for the treatment, amelioration or prevention of a disease caused by Bacillus anthracis (B anthracis) infection. Furthermore, methods for the treatment of an B. anthracis infection as well as methods of protection against a B. anthracis infection, e.g. a vaccination are described.Type: GrantFiled: July 21, 2005Date of Patent: July 24, 2012Assignee: Max-Planck-Gesellschaft zur Foderung der Wissenschaften E.V.Inventors: Chun Kim, Stefan Kaufmann, Nadesan Gajendran
-
Patent number: 8206726Abstract: Certain zwitterionic polysaccharides, including those naturally expressed by commensal B. fragilis in the gut, interact with cells of the immune system and affect the TH1/TH2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas and supplements, are provided. Also provided is a method of promoting immune system maturation in an infant involving enteral administration of a nutritional formula or nutritional supplement of the invention.Type: GrantFiled: February 5, 2007Date of Patent: June 26, 2012Assignee: The Brigham and Women's Hospital, Inc.Inventors: Dennis L. Kasper, Sarkis K. Mazmanian
-
Patent number: 8202514Abstract: A novel strain of Bacillus subtilis EB120 shows high antagonistic activity for controlling various plant diseases including barley powdery mildew, cucumber powdery mildew, red pepper anthracnose, rice blast, tomato gray mold, tomato late blight and wheat leaf rust, it can be effectively used as a microbioside for biologically controlling the plant diseases.Type: GrantFiled: March 23, 2005Date of Patent: June 19, 2012Assignee: Korea Research Institute of Chemical TechnologyInventors: Kwang Yun Cho, Jin-Cheol Kim, Gyung Ja Choi, Seon-Woo Lee, Yong Ho Choi, Kyoung Soo Jang, He Kyoung Lim
-
Publication number: 20120141526Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.Type: ApplicationFiled: October 30, 2007Publication date: June 7, 2012Applicant: The Regents of the University of MichiganInventors: James R. Baker, Anna Bielinska, Andrzej Myc
-
Patent number: 8192720Abstract: Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.Type: GrantFiled: February 5, 2010Date of Patent: June 5, 2012Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, RenoInventors: Thomas Kozel, William Murphy, Suzanne Brandt, Bruce R. Blazar, Julie A. Lovchik, Peter Thorkildson, Ann Percival, C. Richard Lyons
-
EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES
Publication number: 20120135038Abstract: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.Type: ApplicationFiled: January 15, 2008Publication date: May 31, 2012Inventor: Henry Daniell -
Patent number: 8187611Abstract: The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.Type: GrantFiled: October 5, 2010Date of Patent: May 29, 2012Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Nareen Abboud, Arturo Casadevall
-
Patent number: 8133498Abstract: A polypeptide having ?/? type SASP activity, for use as a medicament.Type: GrantFiled: November 3, 2009Date of Patent: March 13, 2012Assignee: Phico Therapeutics Ltd.Inventor: Heather Marie Fairhead
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Patent number: 8114582Abstract: The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence-labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the fluorescence polarization of a liquid sample.Type: GrantFiled: June 27, 2008Date of Patent: February 14, 2012Assignee: The United States of America as represented by the Secretary of the NavyInventors: Malford E. Cullum, Lloyd G. Simonson, Sylvia Z. Schade, Linda A. Lininger, Alan L. McArthur
-
Publication number: 20120027799Abstract: The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).Type: ApplicationFiled: April 2, 2010Publication date: February 2, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Cynthia L. Sears, Drew M. Pardoll, Shaoguang Wu, Franck Housseau
-
Patent number: 8105613Abstract: Spore coat-associated proteins from members of Bacillus genera, and in particular spore-coat associated protein N (CotN), have utilization as adjuvants in vaccine formulations. The vaccine formulations most likely contain a virulence factor of bacterial origin, which in the case of Bacillus genera is the protective antigen.Type: GrantFiled: March 10, 2006Date of Patent: January 31, 2012Assignee: The Secretary of State for DefenceInventors: Helen Claire Flick-Smith, James Edward Eyles, Emma Louise Waters, Nicola Jane Walker, Ethel Diane Williamson, Leslie William Baillie, Julie Miller
-
Publication number: 20120021004Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.Type: ApplicationFiled: May 25, 2007Publication date: January 26, 2012Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, John L. Alls, Pedro J. Morales
-
Publication number: 20120020993Abstract: The present invention relates to a pharmaceutical formulation comprising lipopolysaccharide derived from Burkholderia thailandensis and its various uses, including but not limited to its use in the treatment and/or prophylaxis of meliodosis or amelioration of symptoms associated therewith, and/or glanders or amelioration of symptoms associated therewith.Type: ApplicationFiled: January 13, 2010Publication date: January 26, 2012Inventors: Joann Lisa Prior, Sarah Victoria Harding, Rachel Elizabeth Dean, Timothy Phillip Atkins
-
Publication number: 20120009219Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: ApplicationFiled: September 23, 2011Publication date: January 12, 2012Inventors: Stephen H. Leppla, Yogendra Singh, Kurt Klimpel, Rachel Schneerson, John B. Robbins
-
Patent number: 8092810Abstract: The present invention relates to the use of polypeptides related to a Bacillus licheniformis polypeptide (amino acids 1-85 of SEQ ID NO: 2) as antimicrobial agents, for example in pharmaceutical applications, including veterinary applications, as well as for preservation, cleaning and disinfection of various surfaces, objects and substances. The polypeptides may in particular be used to treat textiles or laundry, e.g., in detergents, for reducing microbes on textile or laundry, and/or for odor reduction. The invention also relates to use of Bacillus strains producing these polypeptides as antimicrobial agents. Examples of microorganism inhibited by Lento are Gram positive bacterial strains, such as Bacillus cereus, and various species of Corynebacterium, Enterococcus, Micrococcus, Streptococcus, and Staphylococcus.Type: GrantFiled: December 16, 2010Date of Patent: January 10, 2012Assignee: Novozymes A/SInventor: Debbie Yaver
-
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Publication number: 20110318386Abstract: Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins.Type: ApplicationFiled: August 5, 2011Publication date: December 29, 2011Applicant: Montana State UniversityInventors: Barry JACOBSEN, Nina K. Zidack, Rebecca Larson